1012 related articles for article (PubMed ID: 30866102)
1. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
[TBL] [Abstract][Full Text] [Related]
2. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
3. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.
Jacob JS; Shaikh A; Goli K; Rich NE; Benhammou JN; Ahmed A; Kim D; Rana A; Goss JA; Naggie S; Lee TH; Kanwal F; Cholankeril G
Clin Infect Dis; 2023 Feb; 76(4):592-599. PubMed ID: 36221143
[TBL] [Abstract][Full Text] [Related]
4. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
5. Increased Mortality and Graft Loss With Kidney Retransplantation Among Human Immunodeficiency Virus (HIV)-Infected Recipients.
Shelton BA; Mehta S; Sawinski D; Reed RD; MacLennan PA; Gustafson S; Segev DL; Locke JE
Am J Transplant; 2017 Jan; 17(1):173-179. PubMed ID: 27305590
[TBL] [Abstract][Full Text] [Related]
6. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
7. Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.
Sawinski D; Shelton BA; Mehta S; Reed RD; MacLennan PA; Gustafson S; Segev DL; Locke JE
Am J Transplant; 2017 Dec; 17(12):3114-3122. PubMed ID: 28696079
[TBL] [Abstract][Full Text] [Related]
8. Direct-Acting Antiretroviral Therapy in Renal Transplant Recipients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Report of Our Experience and Literature Review.
Moreno-Ramirez M; Villanego F; Vigara LA; Cazorla JM; Naranjo J; Garcia T; Merino MJ; Mazuecos A
Transplant Proc; 2020 Mar; 52(2):523-526. PubMed ID: 32035678
[TBL] [Abstract][Full Text] [Related]
9. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
10. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
11. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
12. A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients.
Locke JE; Mehta S; Reed RD; MacLennan P; Massie A; Nellore A; Durand C; Segev DL
J Am Soc Nephrol; 2015 Sep; 26(9):2222-9. PubMed ID: 25791727
[TBL] [Abstract][Full Text] [Related]
13. Renal transplantation in human immunodeficiency virus-infected recipients: a case-control study from the Brazilian experience.
Vicari AR; Spuldaro F; Sandes-Freitas TV; Cristelli MP; Requião-Moura LR; Reusing JO; Pierrotti LC; Oliveira ML; Girão CM; Gadonski G; Kroth LV; Deboni LM; Ferreira GF; Tedesco-Silva H; Esmeraldo R; David-Neto E; Saitovitch D; Keitel E; Garcia VD; Pacheco-Silva A; Medina-Pestana JO; Manfro RC
Transpl Infect Dis; 2016 Oct; 18(5):730-740. PubMed ID: 27503081
[TBL] [Abstract][Full Text] [Related]
14. Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation.
Yuan Q; Hong S; Perez-Ortiz A; Roth E; Chang DC; Madsen JC; Elias N
J Am Coll Surg; 2020 Jun; 230(6):853-861.e3. PubMed ID: 32035979
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
Manzardo C; Londoño MC; Castells L; Testillano M; Luis Montero J; Peñafiel J; Subirana M; Moreno A; Aguilera V; Luisa González-Diéguez M; Calvo-Pulido J; Xiol X; Salcedo M; Cuervas-Mons V; Manuel Sousa J; Suarez F; Serrano T; Ignacio Herrero J; Jiménez M; Fernandez JR; Giménez C; Del Campo S; Esteban-Mur JI; Crespo G; Moreno A; de la Rosa G; Rimola A; Miro JM;
Am J Transplant; 2018 Oct; 18(10):2513-2522. PubMed ID: 29963780
[TBL] [Abstract][Full Text] [Related]
16. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool.
Dao A; Cuffy M; Kaiser TE; Loethen A; Cafardi J; Luckett K; Rike AH; Cardi M; Alloway RR; Govil A; Diwan T; Sherman KE; Shah SA; Woodle ES
Clin Transplant; 2019 Jul; 33(7):e13598. PubMed ID: 31104346
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series.
Campos-Varela I; Agudelo EZ; Terrault NA
Clin Transplant; 2018 Jul; 32(7):e13303. PubMed ID: 29851150
[TBL] [Abstract][Full Text] [Related]
18. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era.
Cotter TG; Wang J; Lieber SR; Odenwald MA; Rich NE; Marrero JA; Singal AG; Mitchell MC; Aronsohn A; Charlton M; Fung J
Transplant Direct; 2021 Jul; 7(7):e707. PubMed ID: 34124343
[TBL] [Abstract][Full Text] [Related]
19. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
20. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
